This topic contains 0 replies, has 1 voice, and was last updated by 
-
Posts
-
In this column, Reid D’Amico shares background on an investigational CF therapy called SPX-101, developed by Spyryx Biosciences, which has shown promise in early animal studies. Click here to read more from Reid.
What did you think of this column?
You must be logged in to reply to this topic.
